Vitamin E δ-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration

Kazim Husain, Rony A. Francois, Sean Z. Hutchinson, Anthony M. Neuger, Richard Lush, Domenico Coppola, Said Sebti, Mokenge P. Malafa

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration. In this report, we investigated the pharmacokinetics, tumor and pancreatic tissue levels, and toxicity of δ-tocotrienol in mice because of its anti-tumor activity against pancreatic cancer. Following a single oral administration of δ-tocotrienol at 100 mg/kg, the peak plasma concentration (Cmax) was 57 ± 5 μmol/l, the time required to reach peak plasma concentration (T max) was 2 h and plasma half-life (t1/2) was 3.5 h. The δ-tocotrienol was cleared from plasma and liver within 24 h, but delayed from the pancreas. When mice were fed δ-tocotrienol for 6 weeks, the concentration in tumor tissue was 41 ± 3.5 nmol/g. This concentration was observed with the oral dose (100 mg/kg) of δ-tocotrienol which inhibited tumor growth by 80% in our previous studies. Interestingly, δ-tocotrienol was 10-fold more concentrated in the pancreas than in the tumor. We observed no toxicity due to δ-tocotrienol as mice gained normal weight with no histopathological changes in tissues. Our data suggest that bioactive levels of δ-tocotrienol can be achieved in the pancreas following oral administration and supports its clinical investigation in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalPharmacology
Volume83
Issue number3
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Tocotrienols
Vitamin E
Oral Administration
Neoplasms
Pancreas
Pancreatic Neoplasms
Anticarcinogenic Agents
Neuroprotective Agents
Half-Life
Pharmacokinetics
Weights and Measures

Keywords

  • δ-Tocotrienol
  • δ-Tocotrienol, mice
  • Pancreatic cancer
  • Pharmacokinetics
  • Tissue distribution

ASJC Scopus subject areas

  • Pharmacology

Cite this

Husain, K., Francois, R. A., Hutchinson, S. Z., Neuger, A. M., Lush, R., Coppola, D., ... Malafa, M. P. (2009). Vitamin E δ-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration. Pharmacology, 83(3), 157-163. https://doi.org/10.1159/000190792

Vitamin E δ-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration. / Husain, Kazim; Francois, Rony A.; Hutchinson, Sean Z.; Neuger, Anthony M.; Lush, Richard; Coppola, Domenico; Sebti, Said; Malafa, Mokenge P.

In: Pharmacology, Vol. 83, No. 3, 01.02.2009, p. 157-163.

Research output: Contribution to journalArticle

Husain, K, Francois, RA, Hutchinson, SZ, Neuger, AM, Lush, R, Coppola, D, Sebti, S & Malafa, MP 2009, 'Vitamin E δ-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration', Pharmacology, vol. 83, no. 3, pp. 157-163. https://doi.org/10.1159/000190792
Husain, Kazim ; Francois, Rony A. ; Hutchinson, Sean Z. ; Neuger, Anthony M. ; Lush, Richard ; Coppola, Domenico ; Sebti, Said ; Malafa, Mokenge P. / Vitamin E δ-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration. In: Pharmacology. 2009 ; Vol. 83, No. 3. pp. 157-163.
@article{a65012152698495896401c0a3ae73d12,
title = "Vitamin E δ-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration",
abstract = "Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration. In this report, we investigated the pharmacokinetics, tumor and pancreatic tissue levels, and toxicity of δ-tocotrienol in mice because of its anti-tumor activity against pancreatic cancer. Following a single oral administration of δ-tocotrienol at 100 mg/kg, the peak plasma concentration (Cmax) was 57 ± 5 μmol/l, the time required to reach peak plasma concentration (T max) was 2 h and plasma half-life (t1/2) was 3.5 h. The δ-tocotrienol was cleared from plasma and liver within 24 h, but delayed from the pancreas. When mice were fed δ-tocotrienol for 6 weeks, the concentration in tumor tissue was 41 ± 3.5 nmol/g. This concentration was observed with the oral dose (100 mg/kg) of δ-tocotrienol which inhibited tumor growth by 80{\%} in our previous studies. Interestingly, δ-tocotrienol was 10-fold more concentrated in the pancreas than in the tumor. We observed no toxicity due to δ-tocotrienol as mice gained normal weight with no histopathological changes in tissues. Our data suggest that bioactive levels of δ-tocotrienol can be achieved in the pancreas following oral administration and supports its clinical investigation in pancreatic cancer.",
keywords = "δ-Tocotrienol, δ-Tocotrienol, mice, Pancreatic cancer, Pharmacokinetics, Tissue distribution",
author = "Kazim Husain and Francois, {Rony A.} and Hutchinson, {Sean Z.} and Neuger, {Anthony M.} and Richard Lush and Domenico Coppola and Said Sebti and Malafa, {Mokenge P.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1159/000190792",
language = "English (US)",
volume = "83",
pages = "157--163",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Vitamin E δ-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration

AU - Husain, Kazim

AU - Francois, Rony A.

AU - Hutchinson, Sean Z.

AU - Neuger, Anthony M.

AU - Lush, Richard

AU - Coppola, Domenico

AU - Sebti, Said

AU - Malafa, Mokenge P.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration. In this report, we investigated the pharmacokinetics, tumor and pancreatic tissue levels, and toxicity of δ-tocotrienol in mice because of its anti-tumor activity against pancreatic cancer. Following a single oral administration of δ-tocotrienol at 100 mg/kg, the peak plasma concentration (Cmax) was 57 ± 5 μmol/l, the time required to reach peak plasma concentration (T max) was 2 h and plasma half-life (t1/2) was 3.5 h. The δ-tocotrienol was cleared from plasma and liver within 24 h, but delayed from the pancreas. When mice were fed δ-tocotrienol for 6 weeks, the concentration in tumor tissue was 41 ± 3.5 nmol/g. This concentration was observed with the oral dose (100 mg/kg) of δ-tocotrienol which inhibited tumor growth by 80% in our previous studies. Interestingly, δ-tocotrienol was 10-fold more concentrated in the pancreas than in the tumor. We observed no toxicity due to δ-tocotrienol as mice gained normal weight with no histopathological changes in tissues. Our data suggest that bioactive levels of δ-tocotrienol can be achieved in the pancreas following oral administration and supports its clinical investigation in pancreatic cancer.

AB - Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration. In this report, we investigated the pharmacokinetics, tumor and pancreatic tissue levels, and toxicity of δ-tocotrienol in mice because of its anti-tumor activity against pancreatic cancer. Following a single oral administration of δ-tocotrienol at 100 mg/kg, the peak plasma concentration (Cmax) was 57 ± 5 μmol/l, the time required to reach peak plasma concentration (T max) was 2 h and plasma half-life (t1/2) was 3.5 h. The δ-tocotrienol was cleared from plasma and liver within 24 h, but delayed from the pancreas. When mice were fed δ-tocotrienol for 6 weeks, the concentration in tumor tissue was 41 ± 3.5 nmol/g. This concentration was observed with the oral dose (100 mg/kg) of δ-tocotrienol which inhibited tumor growth by 80% in our previous studies. Interestingly, δ-tocotrienol was 10-fold more concentrated in the pancreas than in the tumor. We observed no toxicity due to δ-tocotrienol as mice gained normal weight with no histopathological changes in tissues. Our data suggest that bioactive levels of δ-tocotrienol can be achieved in the pancreas following oral administration and supports its clinical investigation in pancreatic cancer.

KW - δ-Tocotrienol

KW - δ-Tocotrienol, mice

KW - Pancreatic cancer

KW - Pharmacokinetics

KW - Tissue distribution

UR - http://www.scopus.com/inward/record.url?scp=58149361841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149361841&partnerID=8YFLogxK

U2 - 10.1159/000190792

DO - 10.1159/000190792

M3 - Article

C2 - 19142032

AN - SCOPUS:58149361841

VL - 83

SP - 157

EP - 163

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 3

ER -